Addition of a Focal Boost in External Beam Radiotherapy for Locally Advanced Prostate Cancer by Online Adaptive MR-guided Radiotherapy

Launched by RADBOUD UNIVERSITY MEDICAL CENTER · May 12, 2022

Keywords

ClinConnect Summary

The AFFIRM trial is a research study that explores a new way to treat locally advanced prostate cancer using a technique called MR-guided hypofractionated focal boost radiotherapy. This method aims to deliver targeted radiation to the tumor while minimizing side effects, building on previous studies that showed this approach can help patients live longer without their cancer returning. The trial is looking for men aged 18 and older who have been diagnosed with prostate cancer that has specific characteristics visible on imaging tests.

To participate, men must not have had previous radiation treatment in the pelvic area and should be able to undergo an MRI scan. If eligible, participants can expect to receive treatment that is designed to be both effective and safe. It’s important to note that the trial is not yet recruiting participants, but it could offer a promising option for men facing this type of cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Men aged 18 years or older with histologically proven prostate carcinoma
• • Imaging stage T3b (as defined on mpMRI) N0M0
• • Intraprostatic lesion visible on MRI
• • Capable of giving informed consent
• Exclusion Criteria:
• • History of radiotherapy to the pelvis or transurethral resection of the prostate (TURP)
• • Contraindications for MRI according to the guidelines of the local department of Radiology, inability to lay on a treatment table for 45-60 minutes or severe claustrophobia
• • Absence of pre-treatment PSMA PET CT
• • WHO performance score \> 2
• • International Prostate Symptom Score ≥ 15
• • PSA \> 30
• • Prostate volume \>100c